Tarsus Pharma Says First Participant Dosed In Phase 2 Clinical Trial Evaluating TP-05, Investigational Oral Therapy To Prevent Lyme Disease By Killing Lyme-Infected Ticks Before Disease Transmission Occurs

Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) has initiated a Phase 2 clinical trial named Calliope, with the first participant dosed for its investigational oral therapy TP-05 (lotilaner), aimed at preventing Lyme disease by killing infected ticks before transmission. The trial will involve approximately 700 healthy adults at risk for Lyme disease and is designed to assess the safety, tolerability, and pharmacokinetics of TP-05. Enrollment is expected to be completed during the 2026 tick season, with topline results anticipated in the first half of 2027.